All News

A new drug called denosumab may soon give Zometa (zoledronic acid) competition as the standard of care in treating bone metastases in patients with advanced breast cancer. Patients taking denosumab not only had fewer bone complications, but they took longer to develop compared with Zometa, reported researchers of a phase 3 study presented Thursday at the San Antonio Breast Cancer Symposium.

An enzyme called CYP2D6 converts tamoxifen to its active form, and some research has suggested that if the enzyme is blocked, tamoxifen won’t be as effective, thus causing patients to recur sooner than women with normal enzyme activity.

A drug that treats liver and kidney cancers delayed locally recurrent or metastatic HER2-negative breast cancer in two phase 2 studies presented Friday at the San Antonio Breast Cancer Symposium

Studies have suggested that MRI, along with mammography, is the best means of detecting breast cancer earlier among high-risk women.

When Dale Eastman was diagnosed with stage 3 breast cancer in 1990 at age 49, it turned the travel agent and mother into a driven advocate.

Krysti Hughett shares her experience as a breast cancer survivor and advocate.

For ER-positive breast cancer, researchers look to find which drugs work best, how they should be sequenced, and how long they should be taken.

Monitoring and managing effects of transplantation can be a waiting game.

The FDA decides to wait on reviewing Prolia (denosumab) for reducing treatment-related bone loss in breast and prostate cancer patients, but a new study may shed light on the drug’s importance.